Abstract: OBJECTIVES: To evaluate the cost-effectiveness of upadacitinib in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), who have responded inadequately to conventional treatment (NSAIDs), in Greece. METHODS: A cost-effectiveness model,...
Publications
<
Year: 2023
Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
Abstract Background and Objective:Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and...
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
Abstract Objectives: To evaluate the cost-effectiveness of lorlatinib compared to 1st generation anaplastic lymphoma kinase (ALK) TKI crizotinib, and 2nd generation TKIs alectinib and brigatinib, for previously untreated patients with ALK+ advanced Non-Small Cell Lung...
Pediatric Quality of Life Inventory (PedsQL) 3.0 Duchenne Muscular Dystrophy module-Greek Translation: A Quality of Life tool in Duchenne Muscular Dystrophy
Abstract: Purpose: Duchenne Muscular Dystrophy (DMD) is a genetic disorder in boys’ early childhood that adversely affects the cardiac, respiratory, and skeletal muscle’s function and emotional and social functioning as aspects of health-related quality of life...
Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
Abstract: Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent...